South Korea has started distributing stocks of COVID-19 treatment remdesivir that have been donated by Gilead Sciences and plans to begin talks to purchase more supplies in August, reported the Business Times.
Only patients severely ill with Covid-19 are eligible for remdesivir and South Korea currently has 33 such patients, the Korea Centres for Disease Control and Prevention (KCDC) said.
KCDC director Jeong Eun-kyeong noted that patients who developed symptoms in less than 10 days and were suffering from pneumonia and a shortage of oxygen would be considered eligible.
South Korea will consider whether remdesivir should be covered by national health insurance after the purchase negotiations in August, added Jeong.
Gilead recently priced remdesivir at $390 per vial in developed countries.
To read more NewsPoints articles, click here.